873436-91-0

Basic information

• Product Name: 6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine
• Synonyms: 6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine;PU-H 71;8-((6-iodobenzo[d][1,3]dioxol-5-yl)thio)-9-(3-(isopropylaMino)propyl)-9H-purin-6-aMine;PU-H71 Trifluoroacetic Acid;9H-Purine-9-propanamine, 6-amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-;NSC 750424;6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine PU-H71 Trifluoroacetic Acid;PU-H71, >=98%
• CAS NO: 873436-91-0
• Molecular Formula: C18H21IN6O2S
• Molecular Weight: 512.36781
• Product Categories: API;Inhibitors
• Mol File: 873436-91-0.mol

Chemical Properties

• Boiling Point: 650.6±65.0 °C(Predicted)
• Appearance: /
• Density: 1.84
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 10.16±0.29(Predicted)
• CAS DataBase Reference: 6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine(873436-91-0)
• EPA Substance Registry System: 6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine(873436-91-0)

Safety Data

• Hazardous Substances Data: 873436-91-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
PU-H71 is used as a potent Hsp90 inhibitor for its potential anti-cancer therapeutic applications. By inhibiting Hsp90, it can modulate the activity of various cell signaling proteins, leading to the disruption of cancer cell growth and survival.
Used in Neurodegenerative Disease Research:
PU-H71 is used as a potential anti-Parkinson's disease agent. Studies have indicated that Hsp90 inhibitors like PU-H71 may have therapeutic potential in treating neurodegenerative diseases such as Parkinson's by modulating the activity of proteins involved in the disease progression.

Upstream product

• 1240419-78-6 9-(3-bromopropyl)-8-((6-iodobenzo[d][1,3]dioxol-5-yl)thio)-9H-purin-6-amine 
• 75-31-0 isopropylamine 
• 7390-62-7 8-mercaptoadenine 
• 5876-51-7 5-iodo-1,3-benzodioxole 
• 14268-66-7 benzo[1,3]dioxolo-5-ylamine 
• 33918-15-9 3-(isopropylamino)-1-propan-ol 
• 873436-89-6 8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-6-amine 
• 873436-88-5 8-(benzo[1,3]dioxol-5-ylsulfanyl)adenine 
• 905449-67-4 3-(tert-butoxycarbonyl-isopropylamino)propyl tosylate 
• 873437-13-9 tert-butyl N-(3-hydroxypropyl)-N-(isopropyl)carbamate 
• 873437-14-0 {3-[6-amino-8-(6-iodo-benzo[1,3]dioxol-5-ylsulfanyl)-purin-9-yl]-propyl}-isopropyl-carbamic acid tert-butyl ester 

Relevant articles and documents

A facile and efficient synthesis of d6-labeled PU-H71, a purine-scaffold Hsp90 inhibitor

PU-H71 is a purine-scaffold Hsp90 inhibitor currently undergoing late stage preclinical evaluation for the treatment of cancer. In this investigation, we present a simple method for the synthesis of d6-labeled PU-H71 for use as an internal standard to accurately quantitate the drug in biological matrices based on an LC-MS-MS method. PU-H71-d6 was synthesized in five steps using readily available 1,3-dibromopropane-d6 and is an important compound for the advancement of our clinical program. Copyright

Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90

Hsp90 is a chaperone protein that allows cancer cells to tolerate the many components of dysregulated pathways. Its inactivation may result in targeting multiple molecular alterations and, thus, in reverting the transformed phenotype. The PU-class, a purine-scaffold Hsp90 inhibitor series, has been reported to be potent and selective against Hsp90 both in vitro and in vivo models of cancer. Here, a series of this class was synthesized and evaluated as inhibitors of the chaperone. The structure-activity relationship and selectivity for tumor Hsp90 of compounds within the series is presented. The study identifies water soluble derivatives (> 5 mM in PBS pH 7.4) of nanomolar potency (IC50 ～ 50 nM) in cellular and animal models of cancer. Binding affinities of these compounds for Hsp90 correlate well with their biological activities. When administered in vivo to mice bearing MDA-MB-468 human breast cancer xenografted tumors, these agents result in pharmacologically relevant concentrations and, accordingly, in modulation of Hsp90-client proteins in tumors.